Brokerages Expect VBI Vaccines Inc. (NASDAQ:VBIV) to Announce -$0.07 EPS

Brokerages expect VBI Vaccines Inc. (NASDAQ:VBIV) to announce ($0.07) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.08) to ($0.07). VBI Vaccines posted earnings of ($0.06) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 16.7%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, March 1st.

On average, analysts expect that VBI Vaccines will report full-year earnings of ($0.28) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.27). For the next year, analysts expect that the firm will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.33) to ($0.22). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last issued its quarterly earnings data on Monday, November 8th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.26 million. VBI Vaccines had a negative return on equity of 39.02% and a negative net margin of 9,290.20%.

Several equities analysts have issued reports on the company. Jefferies Financial Group assumed coverage on VBI Vaccines in a report on Thursday, December 30th. They set a “buy” rating and a $6.00 price objective on the stock. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Friday, December 31st.

Shares of VBIV stock opened at $2.05 on Wednesday. The stock’s 50-day moving average is $2.55 and its two-hundred day moving average is $2.94. The firm has a market cap of $527.48 million, a price-to-earnings ratio of -7.88 and a beta of 1.87. VBI Vaccines has a 1 year low of $1.86 and a 1 year high of $4.83. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.42 and a current ratio of 4.49.

In other news, major shareholder Perceptive Advisors Llc sold 2,707,463 shares of the stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $3.31, for a total transaction of $8,961,702.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.00% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its position in VBI Vaccines by 360.6% in the second quarter. Squarepoint Ops LLC now owns 186,702 shares of the biopharmaceutical company’s stock valued at $625,000 after purchasing an additional 146,168 shares during the period. Occudo Quantitative Strategies LP lifted its position in VBI Vaccines by 263.6% in the second quarter. Occudo Quantitative Strategies LP now owns 97,518 shares of the biopharmaceutical company’s stock valued at $327,000 after purchasing an additional 70,695 shares during the period. HighTower Advisors LLC lifted its position in VBI Vaccines by 11.7% in the second quarter. HighTower Advisors LLC now owns 45,985 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 4,828 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in VBI Vaccines in the second quarter valued at about $105,000. Finally, Marshall Wace LLP acquired a new stake in VBI Vaccines in the second quarter valued at about $280,000. Hedge funds and other institutional investors own 43.37% of the company’s stock.

About VBI Vaccines

VBI Vaccines, Inc is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response.

See Also: Moving Average Convergence Divergence (MACD)

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.